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Purpose: To compare the sensitivity for breast cancer (BC) and BC size estimation of preoperative
contrast-enhanced magnetic resonance imaging (CEMRI) versus combined unenhanced magnetic reso-
nance imaging (UMRI) and digital breast tomosynthesis (DBT).
Patients and methods: We retrospectively included 56 women who underwent DBT and preoperative
1.5 T CEMRI between January 2016eFebruary 2017. Three readers with 2e10 years of experience in
CEMRI and DBT, blinded to pathology, independently reviewed CEMRI (diffusion-weighted imaging
[DWI], T2-weighted imaging, pre- and post-contrast T1-weighted imaging) and a combination of UMRI
(DWI and pre-contrast T1-weighted imaging) and DBT. We calculated per-lesion sensitivity of CEMRI and
UMRI þ DBT, and the agreement between CEMRI, UMRI and DBT versus pathology in assessing cancer
size (Bland-Altman analysis). Logistic regression was performed to assess features predictive of cancer
missing.
Results: We included 70 lesions (64% invasive BC, 36% ductal carcinoma in situ or invasive BC with in situ
component). UMRI þ DBT showed lower sensitivity (86e89%) than CEMRI (94e100%), with a significant
difference for the most experienced reader only (p ¼ 0.008). False-positives were fewer with UMRI þ DBT
(4e5) than with CEMRI (18e25), regardless of the reader (p ¼ 0.001e0.005). For lesion size, UMRI
showed closer limits of agreement with pathology than CEMRI or DBT. Cancer size 1 cm was the only
independent predictor for cancer missing for both imaging strategies (Odds ratio 8.62 for CEMRI and
19.16 for UMRI þ DBT).
Conclusions: UMRI þ DBT showed comparable sensitivity and less false-positives than CEMRI in the
preoperative assessment of BC. UMRI was the most accurate tool to assess cancer size.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Contrast-enhanced magnetic resonance imaging (CEMRI) has
emerged as the most reliable tool for assessing loco-regional extentrossano.girometti@uniud.it
i), anna.linda@asuiud.sanita.
, federica.bondini@gmail.com
rancesco.sardanelli@unimit.it
n open access article under the Cof breast cancer (BC). Based on superior contrast resolution and the
capability of exploiting tumoral neoangiogenesis [1], CEMRI is
highly sensitive in detecting multicentric, multifocal and bilateral
cancer foci [2,3], as well as in predicting BC size at pathology [4e6].
Despite this, the impact on surgical outcomes of preoperative
CEMRI is disputed [7,8]. On the other hand, this technique is
increasingly used for tailoring the surgical approach [9].
There are several disadvantages limiting the widespread adop-
tion of CEMRI. First, examination specificity is generally regarded as
suboptimal for the purpose of minimizing overdiagnosis and
overtreatment of false-positive (FP) findings, even though second-C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
BC breast cancer
CEMRI contrast enhanced Magnetic resonance imaging
DBT Digital breast tomosynthesis
UMRI unenhanced Magnetic resonance imaging
R1-R3 readers 1 to 3
IQR (interquartile range)
ICC Intraclass correlation coefficient
R. Girometti et al. / The Breast 49 (2020) 174e182 175look ultrasound [10e12] and MRI-guided biopsy [13] enable to
solve these limitations. Second, concerns exist in terms of accessi-
bility and availability, costs, and need for expertise, thus limiting
the use of preoperative CEMRI to selected centres [9]. Finally,
contrast administration is associated with the risk of hypersensi-
tivity reactions, systemic nephrogenic fibrosis, and accumulation/
retention in the central nervous system and other body areas
[14,15].
There is an ever-increasing interest in technical variants of the
examination to overcome the above limitations, including unen-
hanced magnetic resonance imaging (UMRI). By combining T1-
weighted and/or T2-weighted anatomic images with diffusion-
weighted imaging (DWI), UMRI candidates as a faster, cheaper,
and safer tool to detect and characterize BC [16e23]. DWI exploits
the restriction of water molecules diffusivity occurring in BC
environment as compared to normal breast tissue. This translates
into high tumor-to-normal tissue contrast, with high signal in-
tensity of cancer foci on DWI images, and hypointensity on a set of
complementary images calculated after the acquisition, named the
Apparent Diffusion Coefficient (ADC) map [24]. In previous works,
UMRI provided less sensitivity and specificity than CEMRI, though
not at a clinically relevant extent [17,18,20,22,23]. Nevertheless, as
far as we know no prior studies investigated whether the combi-
nation of UMRI with other imaging modalities can increase diag-
nostic accuracy and approximate CEMRI in the preoperative setting.
We hypothesized that digital breast tomosynthesis (DBT) might
complement UMRI effectively. This imaging techniques uses X-ray
exposure to produce multiple thin slices of the breast, thus limiting
the effects of tissue superimposition which can mask or mimic BC
on digital mammography [25]. DBT has shown greater accuracy
than digital mammography in assessing BC size and identifying
additional disease [26,27]. One might assume that combined UMRI
and DBT (UMRI þ DBT) can emphasize the advantages inherent to
each technique, i.e. high contrast resolution for UMRI, and high
spatial resolution for DBT, respectively.
In this light, the main purpose of this study was to compare
CEMRI and UMRI þ DBT in the preoperative assessment of BC in
terms of cancer detection (index lesions and multicentric/multi-
focal cancer foci) and cancer size estimation.
2. Patients and methods
2.1. Study population and standard of reference
The referring Institutional Review Board approved this study,
waiving for the acquisition of the informed consent because of the
retrospective design.
By performing a search between January 2016eFebruary 2017,
we identified all the women referred to surgery for biopsy-proven
BCwho underwent preoperative CEMRI, as required by the policy of
our tertiary referral institution. Of 514 subjects, we excluded those
addressed to neoadjuvant therapy after MRI (n ¼ 7) or showingpost-biopsy changes such as clip-related susceptibility artefacts,
seroma or haemorrhage (n ¼ 128). Other 323 women were
excluded because they did not underwent DBT as prior first-line
imaging, or underwent it monolaterally. Final population
included 56 women with bilateral CEMRI and DBT, presenting a
total of 58 index lesions (i.e., lesions initially prompting CEMRI),
and 12 additional lesions confirmed by subsequent ultrasound-
guided biopsy and/or final pathological examination after surgery.
Of 56 women, 2 showed bilateral index lesions. Among additional
lesions, 9 were found in the same breast quadrant of the index
lesion, while 3 were in a different quadrant. Women showed a
mean age of 58.8 years (±12.3 standard deviation, range 33e81
years).
Pathological analysis was the standard of reference for imaging
findings included in the surgical specimen. Analysis was performed
by a pool of three pathologists with 5e25 years of experience in
breast pathology, who processed surgical specimens and measured
cancer according to the College of American Pathologists guidelines
valid at the time in which surgery was performed (January
2016eFebruary 2017) [28,29]. Imaging follow-up of at least 2 years
served as surrogate standard of reference for those findings not
included in the surgical specimen and assessed as benign (see
below). Imaging included variable combinations of mammography,
ultrasound, DBT and CEMRI.
2.2. Imaging protocols
DBTwas acquired on one of two digital mammography systems:
Giotto TOMO (Internazionale Medico Scientifica, Bologna, Italy);
AW5000 3D Selenia Dimensions (Hologic, Bedford, MA, USA). Each
breast was investigated with standard cranio-caudal and medio-
lateral oblique views, with both systems generating synthetic
two-dimensional (2D) images (s2D) for each view. Table 1 in
Appendix A shows the acquisition parameters of DBT.
CEMRI examinations were performed in the prone position on
one of two 1.5 T magnets: Magnetom Avanto or Magnetom Aera
(Siemens Medical Solutions, Erlangen, Germany), using a bilateral
breast 4-channel or 16-channel coil, respectively. The CEMRI pro-
tocol, which included DWI, pre- and post-contrast T1-weighted
dynamic contrast enhanced imaging (DCE), and T2-weighted im-
aging, is detailed in Table 2 of Appendix A. Using a remote control
injector (OptiStar Elite injector, Mallinckrodt, UK), we administered
gadobenate dimeglumine (Multihance, Bracco, Milan, Italy) intra-
venously, at a dose of 0.1 mmol/kg and an injection rate of 2 ml/s.
2.3. Image analysis
A study coordinator with 4 years of experience in breast imag-
ing, not involved in image analysis, organized reading sessions on
our picture archiving and communication system (PACS) worksta-
tion (SuitEstensa, Ebit AET, Esaote, Genoa, Italy). ADC maps were
generated by the vendor’s software (Leonardo Syngo, Siemens
Medical Systems, Erlangen, Germany). Cases were prompted during
independent and separate reading sessions to three different
readers, including a senior radiologist (R1), and two residents (R2
and R3). R1, R2 and R3 showed 10, 3 and 3 years of experience in
CEMRI and DBT, respectively. Readers were aware of interpreting
preoperative examinations, though they were blinded to prior
imaging and clinical information (including lesions’ number and
type). They accessed two types of examinations: CEMRI alone
(including all the sequences reported in Table 2 of Appendix A) or
UMRI þ DBT. While DBT included native and s2D images for each
view, UMRI was composed by the unenhanced T1-weighted
sequence and DWI. DWI included the following sets of images: 1)
images obtained with low diffusion-weighting (so called low b-
Table 1
Histological type and size of the seventymalignant lesions included in the analysis. IQR¼ interquartile range; IDC¼ invasive ductal carcinoma; DCIS¼ ductal carcinoma in situ;
IDLC¼mixed invasive ductal-lobular carcinoma; ILC¼ invasive lobular carcinoma; LCIS¼ lobular carcinoma in situ. The table note shows the number (n) of histological grades
of IDC, IDC with associated in situ component, DCIS, and DCIS associated to invasive cancer.
Type of lesions Histological type Number of lesions (% on the total of lesions) Median size (cm) IQR
Index cancers (n ¼ 58) IDCa 30 (42.6%) 2.2 13.5e30.0
IDCdþDCISb 18 (25.7%) 1.1 9.0e15.0
IDLC 4 (5.7%) 2.8 16.0e41.0
ILC 1 (1.4%) 1.3 e
ILC þ LCIS 1 (1.4%) 2.1 e
DCISa 4 (5.7%) 6.0 32.0e92.5
Additional cancers (n ¼ 12) Multifocal cancers IDCc 8 (11.4%) 0.9 8.5e12.0
IDCdþDCISb 1 (1.4%) 0.6 e
Multicentric cancers IDCc 2 (2.9%) 1.0 e
DCISa 1 (1.4%) 0.4 e
a DCIS: grade 1 (n ¼ 1), grade 2 (n ¼ 2), and grade 3 (n ¼ 2).
b DCIS component associated to invasive cancer: grade 1 (n ¼ 3), grade 2 (n ¼ 7), and grade 3 (n ¼ 6).
c IDC: grade 1 (n ¼ 4), grade 2 (n ¼ 20), grade 3 (n ¼ 16).
d IDC with associated in situ component: grade 1 (n ¼ 4), grade 2 (n ¼ 13), grade 3 (n ¼ 2).
Table 2
Per-reader distribution of the sensitivity, true positive (TP), false negative (FN), and false positive (FP) cases achieved with contrast-enhanced magnetic resonance imaging
(CEMRI) versus the combination of unenhanced magnetic resonance imaging (UMRI) and digital breast tomosynthesis (DBT). Denominators of the ratios provided in the rows
represent the total number of TP þ FN þ FP cases.
Reader 1 Reader 2 Reader 3
CEMRI UMRI þ DBT pa CEMRI UMRI þ DBT pa CEMRI UMRI þ DBT pa
Sensitivity % (95%C.I.) 100 (0.95e1.00) 88.6 (0.79e0.94) 0.008 94.3 (0.87e0.98) 87.1 (0.77e0.93) 0.180 94.3 (0.87e0.98) 85.7 (0.75e0.92) 0.180
TP 70/92 62/75 0.342 66/95 61/75 0.109 66/88 60/74 0.448
FN 0/92 8/75 0.001 4/95 9/75 0.008 4/88 10/74 0.052
FP 22/92 5/75 0.002 25/95 5/75 0.001 18/88 4/74 0.005
a Significance of the intra-reader comparison between CEMRI versus UMRI þ DBT.
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images with strong diffusion-weighting (so called high b-value
images), which show the highest tumor-to-normal tissue contrast;
3) the ADC map, obtained from low b value and high b-value im-
ages, representing the spatial distribution of the ADC as a measure
of water diffusion in the tissue (the term “apparent” accounts for
several tissue effects making this index different from pure diffu-
sion coefficient [24]). CEMRI or UMRI þ DBT dataset were pre-
sented randomly by separating the readings performed on the
same women by an interval of time of 3 weeks between the two
imaging sets.
For each patient, R1-R3 recorded the site (side and quadrant)
and size (cm) of imaging findings, categorizing them with the
Breast Imaging Reporting and Data System (BI-RADS) for CEMRI
and DBT [24]. Findings were assessed as malignant if scored4. BI-
RADS categorization included also the assessment of breast density
on DBT, and the degree of breast parenchymal enhancement (BPE)
on CEMRI [30]. For the purpose of analysis, breast density and BPE
were defined as “high” when categorized  C and moderate-to-
marked, respectively. Since the BI-RADS is inapplicable to UMRI,
readers referred to the categorization score illustrated in Fig. 1.
When interpreting UMRI þ DBT, a finding was considered as ma-
lignant if assessed as category 4 or larger with at least one of the
two imaging modalities.
Cancer size was measured on the slice showing the largest
diameter when reading CEMRI or DBT. Measurement was per-
formed in the subtracted series showing better lesion conspicuity
in the case of CEMRI, and on the view in which the lesion showed
better visibility in the case of DBT. Spiculae were excluded from
measurement on either CEMRI or DBT [31,32]. On UMRI, lesion
measurement was performed on the slice and image (T1-weighted,high b-value or ADC map) where the observation showed
maximum conspicuity and diameter.2.4. Statistical analysis
After assessing data normality with the Shapiro-Wilk test, we
reported continuous variables as median and interquartile range
(IQR) values. Proportions were reported together with 95% confi-
dence intervals (95%CI).
We calculated the sensitivity for each reader, defined as the
percent ratio between true positive (TP) cases and the sum of TP
and false negative (FN) cases. On an intra-reader basis, we assessed
whether there was any significant difference between CEMRI and
UMRI þ DBT in terms of sensitivity (using the McNemar test), as
well as in the number of TP or FP or FN cases over the total number
of TP þ FP þ FN cases (using the Fisher exact test).
Concerning cancer size, we evaluated CEMRI, DBT and UMRI
separately and on an intra-reader basis. Using the Friedman test, we
assessed whether there was any significant difference in estimating
the size of TP findings that there were detected by all imaging
modalities. On the same set of findings, we used Bland-Altman
analysis to exploit the agreement of each imaging modality with
pathological size. Data underwent logarithmic transformation to
match the prerequisites of analysis [33,34], so that mean bias and
95% limits of agreement betweenmeasurements were presented as
dimensionless values. Bland-Altman analysis was integrated with
the intraclass correlation coefficient (ICC), using the following
reference values for the agreement [35]: 0.40 ¼ poor;
0.40e0.59 ¼ fair; 0.60e0.74 ¼ good; 0.75e1.00 ¼ excellent.
Finally, we built two stepwise logistic regression models for
determining which clinical or imaging variable was predictive of
Fig. 1. Flowchart of the interpreting rules for unenhanced magnetic resonance imaging (UMRI). After evaluating whether the UMRI finding showed “mass” or “non mass”
appearance on T1-weightening (T1-WI), readers attributed the reported score according to the presentation of each image feature (shape, margins, internal characteristics,
appearance on diffusion-weighted imaging [DWI]), until the bottom step was reached. The final score resulted from the sum of each individual score in order to express the risk for
malignancy as follows: final score 0e1 ¼ category 2, definitively benign; final score 2e3 ¼ category 3, probably benign; final score 4e5 ¼ category 4, suspicious of malignancy; final
score 6 ¼ category 5, high suspicious of malignancy. Findings categorized 4 or larger were assumed to be malignant.
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CEMRI or UMRI þ DBT.
Analysis was performed on a commercially available software
(MedCalc Software bvba, version 18.11.6, Ostend, Belgium). Alfa
level was set 0.05, using the Bonferroni correction in the case of
multiple pairwise comparisons.
3. Results
3.1. Cancers characteristics
Included women (n ¼ 56) underwent unilateral mastectomy in
33 cases, bilateral mastectomy in 1 case, unilateral breast-
conserving surgery in 21 cases, and bilateral breast-conserving
surgery in 1 case, respectively.
Table 1 shows the histological type and size of 70 breast cancers
found at pathological examination. Median size of all lesions, index
lesions alone, and additional lesions alone was 1.5 cm (IQR
0.9e3.0 cm), 1.8 cm (IQR 1.1e3.0 cm) and 0.7 cm (IQR 0.5e1.1 cm),
respectively. Overall, cancers size was 1.0 cm in 22/70 lesions
(31.4%), corresponding to 14/58 index lesions, and 8/12 additional
lesions.
3.2. Sensitivity for breast cancer
As shown in Table 2, CEMRI showed higher sensitivity for BC
than UMRI þ DBT (range 94.3e100% versus 85.7e88.6%). The dif-
ference was statistically significant (p ¼ 0.008) in the case of R1
only. FNs induced by UMRI þ DBT were significantly
(p ¼ 0.001e0.008) or nearly significantly (p ¼ 0.052) larger in
number than those induced by CEMRI for R1-R2 and R3,
respectively.
Higher sensitivity of CEMRI was counterbalanced by a signifi-
cantly larger number of FPs compared to UMRIþ DBT, regardless of
the reader (p ranging 0.001e0.005). There was no significant dif-
ference in the number of TPs achieved by both imaging modalities
for each reader. The distribution and characteristics of FN and FPfindings are detailed in Table 3 Appendix A. FP cases were
confirmed by core needle biopsy (CNB), pathological examination if
included in the surgical specimen, or imaging follow-up, as detailed
in Table 3 in Appendix A. All the FP cases included in the surgical
specimen were operated at the time of primary surgery, except for
one B3 lesion found by core needle biopsy (identified by R2 only in
the study), which underwent lumpectomy separately (no atypia at
pathological examination).
Most of CEMRI-induced FPs were avoided by UMRI þ DBT, i.e.
21/22 (95.4%) for R1, 24/25 (96.0%) for R2, and 17/18 (94.4%) for R3.
Exemplificative cases are shown in Figs. 2e3.
Overall, CEMRI and UMRI þ DBT agreed in categorizing cancers
with a score 4 in 62/70 cases for R1 (88.6%; 95%CI 78.2e94.6), 59/
70 cases for R2 (84.3%; 95%CI 73.2e91.5), and 56/70 for R3 (80.0%;
95%CI 68.4e88.3). Agreement in categorizing a finding as suspi-
cious was not investigated with Cohen’s kappa statistic because of
the low number of 3 assignments attributed in common by the
two imaging strategies (0 for R1 and R3, and 2 for R2).
The number of benign findings identified by R1, R2 and R3 was
20 in 18 women, 28 in 15 women, and 23 in 14 women using
CEMRI, and 19 in 17 women, 20 in 18 women and 22 in 16 women
using UMRI þ DBT, respectively. None of those findings was shown
to be malignant over time.3.3. Cancer size
Median (IQR) size of category 4 findings on CEMRI, DBT and
UMRI was 1.5 cm (1.0e3.2), 2.1 cm (1.0e3.0) and 2.0e05 cm
(1.3e3.0) for R1; 1.7 cm (1.1e3.0), 2.0 cm (1.1e3.0) and 2.0 cm
(1.3e3.0) for R2; 1.7 cm (1.1e3.0), 1.8 cm (1.1e2.8) and 2.0 cm
(1.0e3.0) for R3, respectively.
Lesions detected by all imaging modalities were 51/70 for R1,
53/70 for R2, and 43/70 for R3. Among them, there was no signif-
icant difference in size between CEMRI, DBT and UMRI
(p ¼ 0.328e0.826) as interpreted by R1 (median/IQR 2.3/
1.3e3.6 cm, 2.2/1.6e3.0 cm, and 2.1/1.4e3.1 cm, respectively) and
R2 (median/IQR 2.2/1.3e3.1 cm, 2.0/1.1e3.0 cm and 2.1/1.3e3.3 cm,
Table 3
Main characteristics of false negative (FN) and false-positive (FP) cancers achieved by contrast-enhanced magnetic resonance imaging (CEMRI) and unenhanced magnetic
resonance imaging plus digital breast tomosynthesis (UMRIþ DBT). IQR¼ interquartile range; IDC¼ invasive ductal carcinoma; DCIS¼ ductal carcinoma in situ; IDLC¼mixed
invasive ductal-lobular carcinoma; G1 ¼ grade 1; G2 ¼ grade 2; G3 ¼ grade 3.
CEMRI UMRI þ DBT CEMRI and UMRIþ DBT
FN cancers FP
cancers
FN cancers FP
cancers
FNs in
common
FPs in
common
Reader
1
Number 0 22 8 5 0 1
Histological type e e 5 IDC G2, 1 IDC G3, 1 ICD G1þDCIS G2, 1 IDC G2þDCIS G2 e e e
Median size
(IQR) (cm)
e 1.5 (0.7
e2.6)
0.7 (0.5e0.7) 0.8 (0.8
e2.3)
e e
Reader
2
Number 4 25 9 5 2 1
Histological type 1 IDC G2, 1 IDC G3, 1 IDC G2þDCIS
G1, 1 IDLC G2
e 4 IDC G2, 1 IDC G3, 1 DCIS G2, 1 DCIS G3, 1 IDC G2þDCIS G3,
1 IDLC G2
e 1 IDC, 1
IDLC
e
Median size
(IQR) (cm)
0.8 (0.6e0.9) 1.1 (0.9
e1.8)
0.7 (0.5e0.8) 1.0 (0.9
e1.9)
0.5 e
Reader
3
Number 4 18 10 4 0 1
Histological type 2 IDC G2, 1 IDC G3, 1 DCIS G3 e 5 IDC G2, 1 IDC G3, 1 DCIS G2, 1 DCIS G3, 1 IDC G1þDCIS G2,
1 IDC G2þDCIS G2
e e e
Median size
(IQR) (cm)
2.5 (0.8e5.1) 0.9 (0.7
e1.5)
0.7 (0.6e1.4) 1.2 (0.9
e1.8)
e e
Fig. 2. Concordance in assessing cancer between contrast-enhanced magnetic resonance imaging (CEMRI) CEMRI and unenhanced MRI plus digital breast tomosynthesis
(UMRI þ DBT) in a 64-years-old patient with unifocal pathology-proven invasive ductal carcinoma. DBT showed a spiculated mass in the left breast, as evident in the medio-lateral
oblique view (arrow in a). On UMRI, the mass appeared as a well-conspicuous, spiculated hypointense lesion on T1-weighted transverse imaging (arrow in b), with restricted
diffusion on the transverse high b-value image (arrow in c) (apparent diffusion coefficient map not shown). On the CEMRI subtracted T1-weighted imaging (arrow in d), the lesion
appeared as a mass with intense contrast enhancement.
Fig. 3. Discordance between CEMRI and UMRI þ DBT in a 51-years-old womanwith invasive ductal carcinoma (G3). UMRI þ DBT showed a single lesion in the upper-outer quadrant
of left breast, presenting as a spiculated mass on DBT (arrow in a) and with hyperintensity on transverse diffusion weighted imaging (b-value 1000 s/mm2) (arrow in b). On CEMRI,
transverse T1-weighted post-contrast subtracted image confirmed the lesion (arrow in c) while showing two additional foci of contrast enhancement on the same breast (<5 mm in
diameter), interpreted as suspicious by the readers (dotted arrows in c). Additional findings were finally assessed as false positives, being not confirmed at subsequent second-look
ultrasound and final pathology.
R. Girometti et al. / The Breast 49 (2020) 174e182178respectively). In the case of R3, CEMRI provided significantly
(p ¼ 0.002) larger size (median/IQR 2.2/1.3e3.1 cm) than DBT
(median/IQR 1.9/1.3e2.9 cm) and UMRI (median/IQR 2.0/
1.4e3.1 cm).The results from agreement analysis (Fig. 4) showed that,
regardless of the reader, UMRI alone showed narrower limits of
agreement and higher ICC values compared, in the descending or-
der, to CEMRI and DBT alone. ICCs showed a similar trend (Fig. 4),
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(0.82e0.87) versus good agreement for CEMRI (0.71e0.77), and
fair-to-good agreement for DBT (0.45e0.65). Mean bias at Bland-
Altman analysis was minimal, regardless of the imaging method.3.4. Cancer missing
The number and main characteristic of cancers missed by each
reader are reported in Table 3. Cancersmissed by at least one reader
were 8/70 for CEMRI, and 12/70 for UMRI þ DBT, respectively.
All readers categorized breast density as BI-RADS B, C and D in 8/
56, 34/56, and 14/56 patients, respectively. Readers agreed also in
assessing BPE as minimal in 32/56 women, mild in 10/56 women,
moderate in 11/56 women, and marked in 3/56 women,
respectively.
At multivariate analysis (Table 4), smaller lesions size (1.0 cm)
was the only independent predictor of missing cancer for both
CEMRI and UMRI þ DBT, though odds ratio (OR) values showed
wide 95%CIs.4. Discussion
In our study, the sensitivity of UMRI þ DBT in the preoperative
assessment of BC was high (range 85.7e88.6%), even if inferior to
that of CEMRI (range 94.3e100%). The difference was statistically
significant in the case of the most experienced readers (R1) only
(p¼ 0.008), possibly because less experienced readers missedmore
cancers even when using the standard imaging of CEMRI, thus
reducing the gap in sensitivity as compared to UMRI þ DBT. How-
ever, CEMRI provided a nearly significant-to-significant
(p ¼ 0.001e0.052) lower number of FN cases, regardless of the
reader. On the bright side, all readers achieved significantly
(p ¼ 0.001e0.005) less FP findings than CEMRI when using
UMRI þ DBT. Our results suggest that UMRI þ DBT can be a reliable
diagnostic alternative to CEMRI in the preoperative assessment of
BC, while carrying some specific advantages of UMRI. Indeed, UMRI
is a mean to reduce the acquisition time and costs related to
contrast medium administration [36]. Its use might potentially
increase the accessibility to preoperative breast MRI, and in turn
expand current indications [37]. Moreover, avoiding contrast
administration would eliminate safety concerns, as exemplified at
best in those patients in which gadolinium chelates should be used
with caution because of impaired renal function, risk for adverse
reaction, or risk for accumulation in the central nervous system
[14,15].
Results on sensitivity were expected, given the well-known
superiority of CEMRI in detecting foci of tumoral neoangiogenesis
[1e3]. Not surprisingly, they are in line with previous studies
comparing UMRI alone versus CEMRI, either using different
unenhanced protocols (range of sensitivity 50.0e93.8% versus
86.0e98.%, respectively) [17,18,20,22,23], or investigating a similar
combination of a T1-weighted sequence and DWI (range of sensi-
tivity 78.4e91.6%) [16,23]. However, we found that the absolute
concordance rate between the two imaging strategies was
comparably high across the readers (range 80.0e88.6%), suggesting
a substantial and reproducible agreement in categorizing imaging
findings, regardless of the radiologist’s experience.
We did not calculate specificity, given the ambiguity of this in-
dex in a context with 100% cancer prevalence. However, our results
on FP findings are reasonably in contrast with previous results onFig. 4. Bland-Altman plots of cancer size measurements obtained by CEMRI, UMRI and DB
limits of agreement compared to pathology are reported as dimensionless values given loga
together with 95% confidence intervals (95%C.I.).specificity. While DBT was shown to be more specific than CEMRI
(88.2% versus 74.2%) [38], UMRI alone showed overlapping or even
lower specificity in studies of direct comparisonwith CEMRI (range
71.4e89.3% versus 76.8e92.8%). A possible explanation for the
discrepancy is that, differently from those studies, readers were
aware of interpreting preoperative examinations, and in turn of the
presence of BC. This scenario was affected by the unavoidable
detection bias related to the higher likelihood that an imaging
finding was malignant [39]. In this scenario, which reflects clinical
practice, UMRI þ DBT avoided most FPs induced by CEMRI, at a
comparable extent in all readers. It should be pointed that the
median size of CEMRI-induced FPs was small (range 0.9e1.5 cm for
R1-R3). This finding matches with the results of logistic regression,
showing that smaller BC size was the only independent predictor of
cancer missing, at a larger extent for UMRI þ DBT than CEMRI (OR
19.16 versus 8.62, respectively). Our results suggest that
UMRI þ DBT has the potential of avoiding small FPs induced by
CEMRI, and in turn reducing additional “second-look” imaging or
biopsy needed for ruling out malignancy [10e12]. This would
further limit costs, patient anxiety, and the overall time from
diagnosis to surgery, though the role for UMRIþ DBT in this setting
should be confirmed in further studies.
Onemight askwhich imaging should represent the reference for
providing cancer size when using combined UMRI and DBT. Ac-
cording to Bland-Altman analysis, both techniques showed slight
mean bias versus pathology, though UMRI provided closer limits of
agreement, i.e. minor expected discrepancy compared to patho-
logical size. This result was reasonably related to the higher tumor-
to-normal tissue contrast that is achieved with DWI, in which
cancer tends to appear as a hyperintense focus over a low-signal
background on high b-value images [17]. Regardless of the
readers and their experience, UMRI predicted pathological size
better than CEMRI, both in terms of limits of agreement and ICCs
(range moderate-to-excellent). A possible explanation is that the
absence of contrast avoided peritumoral inflammation-related
enhancement as a source of size overestimation [40,41]. This hy-
pothesis is in line with larger lesion size we observed with CEMRI
than UMRI.
This study suffers from several limitations. First, we excluded a
large number of patients (n ¼ 128) with post-biopsy artefacts on
CEMRI (and in turn UMRI), thus potentially limiting the applica-
bility of our results to the real clinical scenario, in which the ex-
amination is usually performed after breast biopsy. Including those
patient was at risk of unblinding the readings by showing the site of
the index lesion, which corresponds by definition to that of the
artefact. We believe this limitation further emphasizes the poten-
tial benefit of preoperative combination of DBT and UMRI, since the
former, which is usually available as a pre-biopsy examination,
might compensate for the artefacts affecting UMRI. Second, we did
not weight the relative impact of UMRI and DBT in providing final
diagnosis, thus making difficult to understand the differential role
in the combined imaging strategy. However, it is reasonably
assuming that main role for UMRI was cancer detection, given high
contrast resolution inherent to the technique (especially DWI),
while DBT better exploited lesions’ morphology. Of note, higher
breast density did not impair cancer detection according to multi-
variate analysis, suggesting that lesions potentially missed by DBT
can be complementary diagnosed by UMRI, whose image contrast
is inherently unaffected by the amount of fibroglandular tissue.
Finally, our study prevalently included invasive ductal carcinomas,T for reader 1 (R1) (aec), reader 2 (R2) (def), and reader 3 (R3) (geh). Mean bias and
rithmic transformation. Intraclass correlation coefficient (ICC) values are reported too,
Table 4
Results of logistic regression analysis aiming to identify predictors of cancer missing. Breast parenchymal enhancement (BPE) was inapplicable to the UMRI þ DBT model.
OR ¼ odds ratio.
Lesions missed by CEMRI Lesions missed by UMRI þ DBT
Univariate analysisa Multivariate analysis Univariate analysisa Multivariate analysis
Age  <49 years 2/16 (12.5%)
 50e69 years 5/32 (15.6%)
 >70 years 1/22 (4.5%)
p ¼ 0.386
e  <49 years 4/16 (25%)
 50e69 years 5/32 (15.6%)
 >70 years 3/22 (13.6%)
p ¼ 0.625
e
High breast density (BI-
RADS C)
8/48 (16.7%) p ¼ 0.043 e 9/48 (18.7%) p ¼ 0.600 e
High BPE (moderate-to-
marked)
2/19 (10.5%) p ¼ 0.885 e Not included Non included
Invasive histology 7/65 (10.7%) p ¼ 0.534 e 10/65 (15.4%) p ¼ 0.162 e
Size 1.0 cm 6/22 (27.3%) p ¼ 0.005 p ¼ 0.012 OR 8.62 (95%CI 1.58
e47.13)
10/22 (45.5%) p < 0.0001 p ¼ 0.0004 OR 19.16 (95%CI 3.69
e99.38)
Being an additional lesion 1/12 (8.3%) p ¼ 0.713 e 5/12 (41.6%) p ¼ 0.013 e
a Chi-square test.
R. Girometti et al. / The Breast 49 (2020) 174e182 181alone or in combinationwith non-invasive components, suggesting
that the generalizability of our results should be proven in series
encompassing a large number of different histological types,
especially invasive lobular carcinoma, as well as difficult-to-
diagnose lesions with benign-like appearance (e.g., mucinous
tumors).5. Conclusions
Combined UMRI þ DBT showed high sensitivity when per-
forming preoperative assessment of BC. Compared to CEMRI,
sensitivity was expectedly lower, though UMRI þ DBT avoided the
large majority of the FPs induced by the former technique. UMRI
showed the highest agreement with pathology in terms of cancer
size, even with regard to CEMRI, thus appearing as the reference
tool to measure BC in the UMRI þ DBT approach. BC size 1.0 cm
was the only independent predictor of missing cancer for both
imaging strategies. Based on our results, one might propose
UMRI þ DBT as an alternative to CEMRI having the potential of
increasing the accessibility to preoperative breast MRI, facilitating
patients’ workup, and reducing contrast-related risks.Ethical approval
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